Exogene

Exogene is a techbio startup that leverages deep learning to innovate in the field of cancer treatment. The company focuses on TCR-based therapies, which use the body's natural T-cell receptors to eliminate cancerous cells. The challenge lies in identifying safe, high-affinity TCRs that can effectively target cancer cells, a task that traditional methods struggle with. Exogene addresses this issue by using a generative AI platform to mine the TCR sequence space, enabling the discovery of novel, high-affinity, and non-cross-reactive TCRs that can target a range of tumor types.

Exogene operates in the healthcare market, specifically in the cancer treatment sector. Its clients are likely to be healthcare providers, research institutions, and pharmaceutical companies interested in innovative cancer therapies. The business model revolves around the use of AI and deep learning to accelerate the discovery and development of TCR-based therapies. The company generates revenue by licensing its technology and potentially partnering with pharmaceutical companies to bring these therapies to market.

The team at Exogene is composed of experts in computational biology, machine learning, and oncology. The co-founders, Federico and Andrea, bring a wealth of experience in mathematical modelling, molecular biophysics, and AI. The Director of R&D, Muhammad, has a strong background in protein engineering and structural biology. Claudia, with her DPhil in Oncology, contributes her expertise in developing novel imaging agents for cancer diagnosis.

Keywords: Techbio startup, Deep learning, TCR-based therapies, Cancer treatment, Generative AI platform, Healthcare market, Licensing technology, Computational biology, Machine learning, Oncology.